Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

• Steven Le Gouill,
• Monika Długosz-Danecka,
• Simon Rule,
• Pier Luigi Zinzani,
• Andre Goy,
• Stephen D. Smith,
• Jeanette K. Doorduijn,
• Carlos Panizo,
• Bijal D. Shah,
• Andrew J. Davies,
• Richard Eek,
• Eric Jacobsen,
• Arnon P. Kater,
• Tadeusz Robak,
• Preetesh Jain,
• Roser Calvo,
• Lin Tao,
• Michael Wang

Affiliations

Steven Le Gouill

Institut Curie, Paris

Monika Długosz-Danecka

Maria Sklodowska-Curie National Research Institute of Oncology, Krakow

Simon Rule

Plymouth University Medical School, Plymouth, UK; AstraZeneca, Mississauga, Ontario

Pier Luigi Zinzani

IRCCS Azienda Ospedaliero- Universitaria di Bologna Istituto di Ematologia “Seràgnoli”; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna

Andre Goy

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

Stephen D. Smith

University of Washington, Fred Hutchinson Cancer Center, Seattle, WA

Jeanette K. Doorduijn

Erasmus MC Cancer Institute, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam

Carlos Panizo

Hospital Universitario Donostia, San Sebastián

Bijal D. Shah

Moffitt Cancer Center, Tampa, FL

Andrew J. Davies

NIHR/Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine, Southampton

Richard Eek

Border Medical Oncology, Albury, NSW

Eric Jacobsen

Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

Arnon P. Kater

Amsterdam University Medical Center, Amsterdam, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium

Tadeusz Robak

Copernicus Memorial Hospital, Medical University of Lodz, Lodz

Preetesh Jain

MD Anderson Cancer Center, University of Texas, Houston, TX

Roser Calvo

AstraZeneca, Gaithersburg, MD

Lin Tao

AstraZeneca, South San Francisco, CA

Michael Wang

MD Anderson Cancer Center, University of Texas, Houston, TX